
Lymphatica Medtech secures EUR 17.9 million to advance lymphedema treatment
15 October 2024

Lymphatica Medtech, a Lausanne-based clinical-stage company specializing in innovative treatments for lymphedema, has raised EUR 17.9 million in a Series B funding round.
Lymphatica Medtech‘s flagship device, LymphoDrain, is a breakthrough in the treatment of lymphedema. Implanted subcutaneously using a minimally invasive technique, it replaces the natural function of lymphatic vessels and actively drains lymphatic fluid to reduce swelling and provide relief to patients. The device aims to revolutionize lymphedema treatment options, which currently include limited and often ineffective therapies.
The funding round was co-led by Panakès Partners, TechWald Next S.p.A., and CDP Venture Capital’s Digital Transition Fund, with participation from OCCIDENT, Zürcher Kantonalbank, and Club Degli Investitori. Existing investors, including High-Tech Gründerfonds (HTGF), also joined the round.
The investment will also support Lymphatica’s international expansion with a new subsidiary in Italy to manage research and development (R&D), manufacturing and clinical operations. This move further strengthens the company’s ability to meet growing demand and scale its pioneering solutions.
Lymphatica’s leadership team has been strengthened with the appointment of Dan Rose as Chairman of the Board. Rose brings extensive experience from previous roles at LimFlow, Direct Flow Medical and Medtronic. Other new board members include Alessio Beverina, Managing Partner at Panakès, and Lukas Guenther, Chief Investment Officer at TechWald Next.
Dr. Marco Pisano, CEO and co-founder of Lymphatica, expressed his excitement about the company’s future: “This funding enables us to push forward with the clinical development of our technology, bringing us closer to delivering a transformative solution for patients with lymphedema.”